Genetic & Diagnostic Testing
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
63
NCT05077709
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
Phase: Phase 2
Role: Collaborator
Start: Feb 14, 2022
Completion: Nov 30, 2024
Loading map...